Scientists in academic or other institutions use the unique insights patients provide to inform their research. Pharmaceutical companies oftentimes look for customer input primarily in late development stages. So far however, their main focus has
Click to read >>>
It can be difficult for public health insurers to decide which medical interventions to cover. After all, it is the tax payers’ money that must be spent wisely and equitably across all patient groups.
Check out the monthly newsletter! It contains my last vlog, summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
Transgender health management has seen important advances in the recent past. Some notable remaining issues revolve around the standard of care and insurance coverage.
Check out the new monthly newsletter! It contains my last vlog, summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
If current organ donation systems don’t adapt, alternative solutions to the global organ shortage will hopefully emerge from biotechnology. Making organ donation work? Organ shortage is costly in terms of human lives, public expenditure and
Continue …Organ donation part 4/4 – Making transplant organs
This is a comment on the following publication: Erik Malmqvist (2019) “Paid to Endure”: Paid Research Participation, Passivity, and the Goods of Work, The American Journal of Bioethics, 19:9, 11-20, DOI:10.1080/15265161.2019.1630498
It has been argued for decades that meaningful incentives are needed for substantially more individuals to donate organs. Existing and hypothetical approaches to improve organ supply are outlined below.